Moderna(US:MRNA) The Motley Fool·2025-07-04 19:07Core Viewpoint - Moderna has experienced a significant increase in stock value, gaining over 12% recently, driven by positive developments in its vaccine research [1]. Group 1: Vaccine Development - Moderna published results from a late-stage study of its seasonal flu vaccine, mRNA-1010, which demonstrated a stronger immune response compared to standard flu vaccines [2]. - The company plans to resubmit its application for a combination COVID-19/flu vaccine, following the withdrawal of its previous application in May [4]. - CEO Stéphane Bancel highlighted the trial results as a significant milestone in reducing influenza burden in older adults [5]. Group 2: Market Sentiment - Despite the positive news regarding the flu vaccine, there is skepticism about whether this development alone will make Moderna's stock a compelling buy [5]. - The company has a robust pipeline of development programs, which could enhance the attractiveness of its shares if any show promise [6].